MX2011011290A - Tratamiento ex-vivo de trastornos inmunologicos con inhibidores de pkc-teta. - Google Patents
Tratamiento ex-vivo de trastornos inmunologicos con inhibidores de pkc-teta.Info
- Publication number
- MX2011011290A MX2011011290A MX2011011290A MX2011011290A MX2011011290A MX 2011011290 A MX2011011290 A MX 2011011290A MX 2011011290 A MX2011011290 A MX 2011011290A MX 2011011290 A MX2011011290 A MX 2011011290A MX 2011011290 A MX2011011290 A MX 2011011290A
- Authority
- MX
- Mexico
- Prior art keywords
- pkc
- immunological disorders
- vivo treatment
- theta
- theta inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describe un método para tratar una diversidad de enfermedades y trastornos mediados o sostenidos a través de la actividad de PKC-teta, incluyendo trastornos inmunológicos y aterosclerosis. Específicamente, la invención se refiere a un método para tratar un trastorno inmunológico o la aterosclerosis en un paciente, que comprende tratar la sangre del paciente, o un componente definido de dicha sangre, con un inhibidor de PKC-teta ex vivo y luego re-administrar la sangre tratada al paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17323709P | 2009-04-28 | 2009-04-28 | |
PCT/US2010/032707 WO2010126967A1 (en) | 2009-04-28 | 2010-04-28 | Ex-vivo treatment of immunological disorders with pkc-theta inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011290A true MX2011011290A (es) | 2012-02-13 |
Family
ID=42332785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011290A MX2011011290A (es) | 2009-04-28 | 2010-04-28 | Tratamiento ex-vivo de trastornos inmunologicos con inhibidores de pkc-teta. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120196919A1 (es) |
EP (1) | EP2445503A1 (es) |
JP (1) | JP2012525403A (es) |
KR (1) | KR20120005460A (es) |
CN (1) | CN102421435A (es) |
AU (1) | AU2010241701A1 (es) |
BR (1) | BRPI1014775A2 (es) |
CA (1) | CA2760305A1 (es) |
CL (1) | CL2011002690A1 (es) |
EA (1) | EA201101568A1 (es) |
IL (1) | IL215939A0 (es) |
MX (1) | MX2011011290A (es) |
NZ (1) | NZ595331A (es) |
WO (1) | WO2010126967A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8251941B2 (en) | 2007-08-31 | 2012-08-28 | The Regents Of The University Of Michigan | Selective cytopheresis devices and related methods thereof |
WO2010135255A1 (en) | 2009-05-18 | 2010-11-25 | Therakos, Inc. | Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases |
UY33473A (es) | 2010-06-28 | 2012-01-31 | Vertex Pharma | Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus |
EP2585448A1 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2012024363A2 (en) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
US20130288370A1 (en) | 2010-10-15 | 2013-10-31 | Cytopherx, Inc. | Cytopheresis cartridges and use thereof |
US20140186372A1 (en) * | 2011-06-16 | 2014-07-03 | La Jolla Institute For Allergy And Immunology | Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases |
TW201317223A (zh) | 2011-07-26 | 2013-05-01 | Vertex Pharma | 噻吩化合物 |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
CA2860831A1 (en) | 2012-01-09 | 2013-07-18 | H. David Humes | Cartridge and method for increasing myocardial function |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
PT2953634T (pt) | 2013-02-07 | 2021-09-02 | Massachusetts Gen Hospital | Métodos de expansão ou depleção das células t reguladoras |
TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
CA2982660C (en) | 2014-11-21 | 2023-01-24 | F2G Limited | 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents |
AU2016263198C1 (en) | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
US10993959B2 (en) | 2015-09-04 | 2021-05-04 | Regents Of The University Of Minnesota | Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) |
WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
CN109476745B (zh) | 2016-05-13 | 2023-11-24 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003032997A1 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
EP1565218A2 (en) * | 2002-11-08 | 2005-08-24 | Tolerrx Inc. | Molecules preferentially associated with effector t cells and methods of their use |
JP2006515014A (ja) * | 2003-01-30 | 2006-05-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | PKC−θのインヒビターとして有用な2,4−ジアミノピリミジン誘導体 |
US7601714B2 (en) * | 2004-07-08 | 2009-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
-
2010
- 2010-04-28 US US13/266,757 patent/US20120196919A1/en not_active Abandoned
- 2010-04-28 MX MX2011011290A patent/MX2011011290A/es not_active Application Discontinuation
- 2010-04-28 EA EA201101568A patent/EA201101568A1/ru unknown
- 2010-04-28 NZ NZ595331A patent/NZ595331A/xx not_active IP Right Cessation
- 2010-04-28 CA CA2760305A patent/CA2760305A1/en not_active Abandoned
- 2010-04-28 EP EP10717377A patent/EP2445503A1/en not_active Withdrawn
- 2010-04-28 WO PCT/US2010/032707 patent/WO2010126967A1/en active Application Filing
- 2010-04-28 JP JP2012508629A patent/JP2012525403A/ja active Pending
- 2010-04-28 KR KR1020117023974A patent/KR20120005460A/ko not_active Application Discontinuation
- 2010-04-28 CN CN2010800185205A patent/CN102421435A/zh active Pending
- 2010-04-28 BR BRPI1014775A patent/BRPI1014775A2/pt not_active IP Right Cessation
- 2010-04-28 AU AU2010241701A patent/AU2010241701A1/en not_active Abandoned
-
2011
- 2011-10-26 IL IL215939A patent/IL215939A0/en unknown
- 2011-10-27 CL CL2011002690A patent/CL2011002690A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1014775A2 (pt) | 2016-04-19 |
CL2011002690A1 (es) | 2012-04-27 |
JP2012525403A (ja) | 2012-10-22 |
CA2760305A1 (en) | 2010-11-04 |
CN102421435A (zh) | 2012-04-18 |
EP2445503A1 (en) | 2012-05-02 |
EA201101568A1 (ru) | 2012-05-30 |
IL215939A0 (en) | 2012-01-31 |
WO2010126967A1 (en) | 2010-11-04 |
NZ595331A (en) | 2013-08-30 |
KR20120005460A (ko) | 2012-01-16 |
US20120196919A1 (en) | 2012-08-02 |
AU2010241701A1 (en) | 2011-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011290A (es) | Tratamiento ex-vivo de trastornos inmunologicos con inhibidores de pkc-teta. | |
HRP20180660T1 (hr) | Sustavi i postupci za liječenje tkiva prostate | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
MX340515B (es) | Terapia antidiabética vasoprotectora y cardioprotectora. | |
EP2352452A4 (en) | SYSTEMS AND METHOD FOR TREATING PROSTATE TISSUE | |
MX2010006363A (es) | Sistemas, aparatos, metodos y procedimientos para el tratamiento no invasivo de tejido usando energia de microondas. | |
MY173994A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
MX2010012860A (es) | Metodos para tratar cancer del sistema nervioso central. | |
EP4275752A3 (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
MX2013007171A (es) | Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. | |
IN2014DN08385A (es) | ||
WO2012016229A3 (en) | Oxytocin treatment to improve memory and modify blood glucose | |
EP2656853A4 (en) | METHOD FOR THE TREATMENT OF ACUTE BRAIN AND BACK-MARK BLOODING DISORDERS OF ISCHEMIC OR HEMORRHAGIC NATURE | |
WO2012129145A8 (en) | Nsclc combination therapy | |
WO2014106772A3 (ru) | Фармацевтическая композиция для лечения гиперплазии предстательной железы | |
WO2012170664A3 (en) | Methods of cancer treatment and prevention through the modulation of sirt4 activity | |
MX371198B (es) | Terapia antidiabetica vasoprotectora y cardioprotectora. | |
NZ628130A (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
UA35658U (ru) | Способ хирургического лечения анальной трещины | |
UA68841U (ru) | Способ хирургического лечения варикоцеле | |
GB201018154D0 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |